STOCK TITAN

Verve Therapeutics Inc - VERV STOCK NEWS

Welcome to our dedicated news page for Verve Therapeutics (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Verve Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Verve Therapeutics's position in the market.

Rhea-AI Summary
Verve Therapeutics granted equity awards to six new employees under the 2024 Inducement Stock Incentive Plan. The awards include stock options for 91,200 shares and 45,800 restricted stock units, with an exercise price of $13.28 per share. The options have a 10-year term and will vest over four years, while the RSUs will vest annually over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Verve Therapeutics grants equity awards to new employees under the 2024 Inducement Stock Incentive Plan, with 16,300 RSUs vested over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.76%
Tags
none
-
Rhea-AI Summary
Verve Therapeutics reports pipeline updates and financial results for Q4 2023, with $624 million in cash, proof-of-concept data for VERVE-101, and upcoming clinical trials for PCSK9 and ANGPTL3 in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.47%
Tags
earnings
Rhea-AI Summary
Verve Therapeutics CEO to participate in fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference. The company is pioneering a new approach to cardiovascular disease with single-course gene editing medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
conferences
-
Rhea-AI Summary
Verve Therapeutics (VERV) to Present at J.P. Morgan Healthcare Conference on January 8, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
conferences
-
Rhea-AI Summary
Verve Therapeutics, Inc. (Nasdaq: VERV) has successfully closed an underwritten public offering of 14,375,000 shares of its common stock at a public offering price of $10.00 per share, resulting in total gross proceeds of approximately $143.8 million. Additionally, the company announced the closing of a private placement of 2,296,317 shares of its common stock to Eli Lilly and Company, at a price per share equal to the public offering price, totaling approximately $23.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
Rhea-AI Summary
Verve Therapeutics, Inc. (Nasdaq: VERV) announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, for total gross proceeds of $125.0 million. In addition, Verve has agreed to sell 2,296,317 shares of its common stock to Eli Lilly and Company in a private placement, resulting in aggregate gross proceeds of approximately $148.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
offering
-
Rhea-AI Summary
Verve Therapeutics, Inc. (Nasdaq: VERV) has commenced an underwritten public offering of shares of its common stock and intends to sell up to $35 million of its common stock to Eli Lilly and Company in a private placement. The company also plans to grant the underwriters a 30-day option to purchase additional shares. Jefferies, Guggenheim Securities, William Blair, BMO Capital Markets, and RBC Capital Markets are acting as joint book-running managers for the public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
offering
-
Rhea-AI Summary
Verve Therapeutics, Inc.: First human proof-of-concept data for in vivo base editing from the ongoing heart-1 phase 1b clinical trial of VERVE-101 revealed LDL-C reductions of up to 55% and blood PCSK9 protein reductions of up to 84%. The safety profile supports continued development of VERVE-101, with enrollment ongoing in the 0.45 mg/kg and 0.6 mg/kg cohorts and plans to initiate an expansion cohort in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Verve Therapeutics, Inc. has made significant progress in developing single-course gene editing medicines for cardiovascular disease, with FDA clearing its Investigational New Drug Application for VERVE-101 in HeFH patients. Verve also announced an expanded collaboration with Eli Lilly and Company and the acquisition of product rights to Verve's PCSK9 and ANGPTL3 programs. The company reported $485.2 million in cash, cash equivalents, and marketable securities, ensuring cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.83%
Tags
earnings
Verve Therapeutics Inc

Nasdaq:VERV

VERV Rankings

VERV Stock Data

1.10B
66.88M
7.65%
88.06%
14.97%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Cambridge

About VERV

verve therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. the company brings together human genetics analysis and gene editing – two of the biggest breakthroughs in 21st century biomedicine – to develop transformative therapies for coronary heart disease. verve is developing medicines, administered once in life, to safely edit the genome of adults to permanently lower ldl cholesterol and triglyceride levels and thereby treat coronary heart disease. founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, verve is backed by a top-tier syndicate of investors, including gv (formerly google ventures), arch venture partners, f-prime capital, biomatics capital, wellington management, casdin capital, and partners innovation fund. the company was recognized as a "2020 best places to work" by the boston business journal. verve is headquartered in cambridge, massachusetts.